Evelo Biosciences
Evelo Biosciences raises $75M Series D at $500M valuation
Quick Facts
Evelo Biosciences: Series D Funding Round
Evelo Biosciences has successfully raised $75M in Series D funding, reaching a valuation of $500M.
Company Overview
Monoclonal microbials for cancer and inflammation
Funding Details
The Series D round was led by Fidelity, with participation from Celgene, Kaiser Permanente Ventures, Flagship Pioneering.
Company Information
- Headquarters: 620 Memorial Drive, Cambridge, MA 02139
- Founded: 2014
- Employees: 150+
- Category: Biotech
Investment
Evelo Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Fidelity: Verified investor in Series D
- Celgene: Verified investor in Series D
- Kaiser Permanente Ventures: Verified investor in Series D
- Flagship Pioneering: Verified investor in Series D
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...